$ATXI
AVENUE THERAPEUTICS, INC.

2024 Q1 Form 10-K Financial Statement

#000143774924008294 Filed on March 18, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.316M $1.137M $4.179M
YoY Change 33.74% -66.23% -21.81%
% of Gross Profit
Research & Development $2.392M $982.0K $6.131M
YoY Change 96.87% 227.33% 127.24%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.392M $2.119M $6.131M
YoY Change 96.87% 606.33% 127.24%
Operating Profit -$3.708M -$14.54M
YoY Change -42.32% 80.78%
Interest Expense $49.00K $22.00K -$206.0K
YoY Change -104.18% -99.5% -104.64%
% of Operating Profit
Other Income/Expense, Net -$641.0K $2.714M $4.258M
YoY Change -45.35% -51.36% -23.69%
Pretax Income -$4.349M $617.0K -$10.49M
YoY Change -42.79% 17.75% 191.09%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.349M $640.0K -$10.49M
YoY Change -42.79% 11.3% 195.27%
Net Earnings / Revenue
Basic Earnings Per Share -$15.40 -$0.98
Diluted Earnings Per Share -$7.72 $0.03 -$0.98
COMMON SHARES
Basic Shares Outstanding 44.26M 13.25M 10.59M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.194M $1.783M $1.783M
YoY Change -61.22% -73.42% -73.42%
Cash & Equivalents $3.194M $1.783M $1.783M
Short-Term Investments
Other Short-Term Assets $116.0K $67.00K $67.00K
YoY Change -41.41% -51.09% -51.09%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.310M $1.850M $1.850M
YoY Change -60.81% -72.97% -72.97%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.310M $1.850M $1.850M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $3.310M $1.850M $1.850M
YoY Change -60.81% -72.97% -72.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $662.0K $78.00K $78.00K
YoY Change 100.61% -39.53% -76.85%
Accrued Expenses $337.0K $532.0K $532.0K
YoY Change -92.6% -15.96% -15.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.412M $1.196M $1.196M
YoY Change -86.68% -66.58% -66.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.412M $1.196M $1.196M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.412M $1.196M $268.0K
YoY Change -86.68% -66.58% -90.88%
SHAREHOLDERS EQUITY
Retained Earnings -$95.30M -$90.90M
YoY Change 8.17% 12.78%
Common Stock $0.00 $3.000K
YoY Change -100.0% -100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.836M $1.582M $1.582M
YoY Change
Total Liabilities & Shareholders Equity $3.310M $1.850M $1.850M
YoY Change -60.81% -72.97% -72.97%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$4.349M $640.0K -$10.49M
YoY Change -42.79% 11.3% 195.27%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$3.120M -$2.324M -$9.451M
YoY Change 98.35% -44.26% 24.42%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$3.000M
YoY Change
Cash From Investing Activities $0.00 -$3.000M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $4.531M 3.946M $7.526M
YoY Change 46.11% -62.98% -28.6%
NET CHANGE
Cash From Operating Activities -$3.120M -2.324M -$9.451M
Cash From Investing Activities 0.000 -$3.000M
Cash From Financing Activities $4.531M 3.946M $7.526M
Net Change In Cash $1.411M 1.622M -$4.925M
YoY Change -7.66% -75.01% -267.23%
FREE CASH FLOW
Cash From Operating Activities -$3.120M -$2.324M -$9.451M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
250000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
250000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
250000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
250000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023 dei Auditor Name
AuditorName
KPMG LLP
CY2023 dei Auditor Location
AuditorLocation
New York, NY
CY2023 dei Auditor Firm
AuditorFirmId
185
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1783000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6708000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
67000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
137000 usd
CY2023Q4 us-gaap Assets
Assets
1850000 usd
CY2022Q4 us-gaap Assets
Assets
6845000 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25597622
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25597622
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4773841
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4773841
CY2022Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 usd
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-38114
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-4113275
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
1111 Kane Concourse, Suite 301
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Bay Harbor Islands
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33154
CY2023 dei City Area Code
CityAreaCode
781
CY2023 dei Local Phone Number
LocalPhoneNumber
652-4500
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023 dei Trading Symbol
TradingSymbol
ATXI
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
8522013 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44260667
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
586000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
2609000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1196000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3579000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
1196000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
3579000 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
92507000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
84456000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90928000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80551000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1582000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3905000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-928000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-639000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
654000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3266000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1850000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6845000 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6131000 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2698000 usd
CY2023 atxi Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
4230000 usd
CY2022 atxi Research And Development Expense For Licenses Acquired
ResearchAndDevelopmentExpenseForLicensesAcquired
0 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4179000 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5345000 usd
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-14540000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-8043000 usd
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
126000 usd
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
20000 usd
CY2023 atxi Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
332000 usd
CY2022 atxi Financing Costs Warrant Liabilities
FinancingCostsWarrantLiabilities
1160000 usd
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4258000 usd
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5580000 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-10488000 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-3603000 usd
CY2023 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-111000 usd
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-51000 usd
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10377000 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3552000 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.63
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10591636
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2185159
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3451000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
649000 usd
CY2022 atxi Common Shares Issuable Founders Agreement
CommonSharesIssuableFoundersAgreement
526000 usd
CY2022 atxi Shares And Warrants Issued During Period Value
SharesAndWarrantsIssuedDuringPeriodValue
3205000 usd
CY2022 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
1104000 usd
CY2022 atxi Adjustment To Additional Paid In Capital Asset Acquisitions
AdjustmentToAdditionalPaidInCapitalAssetAcquisitions
-99000 usd
CY2022 atxi Adjustment To Additional Paid In Capital Issuance Of Subsidiaries Common Shares For License Expenses
AdjustmentToAdditionalPaidInCapitalIssuanceOfSubsidiariesCommonSharesForLicenseExpenses
4000 usd
CY2022 atxi Stock Issued During Period Value Exercise0f Warrants
StockIssuedDuringPeriodValueExercise0fWarrants
237000 usd
CY2022 atxi Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance
AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance
0 usd
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-51000 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3552000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3266000 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
906000 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
72000 usd
CY2023 atxi Common Shares Issuable Founders Agreement
CommonSharesIssuableFoundersAgreement
371000 usd
CY2023 atxi Stock And Prefunded Warrants Issued During Period Values November2023 Public Offering Net Of Issuance Costs
StockAndPrefundedWarrantsIssuedDuringPeriodValuesNovember2023PublicOfferingNetOfIssuanceCosts
3874000 usd
CY2023 atxi Shares And Warrants Issued During Period Value
SharesAndWarrantsIssuedDuringPeriodValue
866000 usd
CY2023 atxi Stock Issued During Period Value License Expense
StockIssuedDuringPeriodValueLicenseExpense
1230000 usd
CY2023 atxi Adjustment To Additional Paid In Capital Issuance Of Subsidiaries Common Shares For License Expenses
AdjustmentToAdditionalPaidInCapitalIssuanceOfSubsidiariesCommonSharesForLicenseExpenses
6000 usd
CY2023 atxi Stock Issued During Period Value Exercise0f Warrants
StockIssuedDuringPeriodValueExercise0fWarrants
1000 usd
CY2023 us-gaap Noncontrolling Interest Decrease From Deconsolidation
NoncontrollingInterestDecreaseFromDeconsolidation
0 usd
CY2023 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-111000 usd
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10377000 usd
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.01
CY2022Q4 atxi Class Of Warrant Or Right Exercisable During Period
ClassOfWarrantOrRightExercisableDuringPeriod
949900
CY2022Q4 atxi Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
949900
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
654000 usd
CY2023 us-gaap Profit Loss
ProfitLoss
-10488000 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-3603000 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
906000 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
649000 usd
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-4258000 usd
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-5580000 usd
CY2023 atxi Issuance Of Stock Under Founders Agreement
IssuanceOfStockUnderFoundersAgreement
371000 usd
CY2022 atxi Issuance Of Stock Under Founders Agreement
IssuanceOfStockUnderFoundersAgreement
526000 usd
CY2023 atxi Common Stock Issued To Fortress Value
CommonStockIssuedToFortressValue
72000 usd
CY2022 atxi Common Stock Issued To Fortress Value
CommonStockIssuedToFortressValue
0 usd
CY2023 atxi Issuance Of Stock For Licenses Acquired
IssuanceOfStockForLicensesAcquired
1230000 usd
CY2022 atxi Issuance Of Stock For Licenses Acquired
IssuanceOfStockForLicensesAcquired
0 usd
CY2023 atxi Research And Development License Acquried Expense
ResearchAndDevelopmentLicenseAcquriedExpense
3000000 usd
CY2022 atxi Research And Development License Acquried Expense
ResearchAndDevelopmentLicenseAcquriedExpense
0 usd
CY2023 atxi License Expenses Paid In Kind
LicenseExpensesPaidInKind
6000 usd
CY2022 atxi License Expenses Paid In Kind
LicenseExpensesPaidInKind
4000 usd
CY2023 us-gaap Increase Decrease In Due From Other Related Parties Current
IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent
-0 usd
CY2022 us-gaap Increase Decrease In Due From Other Related Parties Current
IncreaseDecreaseInDueFromOtherRelatedPartiesCurrent
-90000 usd
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-70000 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
30000 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9451000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7596000 usd
CY2023 atxi Payments To Acquire Research And Development Licenses
PaymentsToAcquireResearchAndDevelopmentLicenses
3000000 usd
CY2022 atxi Payments To Acquire Research And Development Licenses
PaymentsToAcquireResearchAndDevelopmentLicenses
-0 usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3000000 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2023 atxi Issuance Of Common Stock Prefund Warrants And Warrants
IssuanceOfCommonStockPrefundWarrantsAndWarrants
7525000 usd
CY2022 atxi Issuance Of Common Stock Prefund Warrants And Warrants
IssuanceOfCommonStockPrefundWarrantsAndWarrants
11497000 usd
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
-0 usd
CY2022 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1104000 usd
CY2023 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1000 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
148000 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7526000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10541000 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4925000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2945000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6708000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3763000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1783000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
6708000 usd
CY2023 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
0 usd
CY2022 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
99000 usd
CY2023 atxi Unpaid Offering Costs
UnpaidOfferingCosts
0 usd
CY2022 atxi Unpaid Offering Costs
UnpaidOfferingCosts
14000 usd
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2022Q4 atxi Percentage Of Warrants Issued
PercentageOfWarrantsIssued
0.15 pure
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
545454
CY2022Q4 atxi Percentage Of Warrants Issued
PercentageOfWarrantsIssued
0.15 pure
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
545454
CY2022Q4 atxi Net Proceeds From Issuance Initial Public Offering
NetProceedsFromIssuanceInitialPublicOffering
10.3 usd
CY2023Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
600000 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90900000 usd
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 pure
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2016Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
250000
CY2016Q3 us-gaap Preferred Stock Dividend Rate Percentage
PreferredStockDividendRatePercentage
0.025 pure
CY2023 atxi Research And Development Expense Licenses Acquired
ResearchAndDevelopmentExpenseLicensesAcquired
300000 usd
CY2023Q1 us-gaap Common Stock Dividends Shares
CommonStockDividendsShares
231316
CY2022 atxi Research And Development Expense Licenses Acquired
ResearchAndDevelopmentExpenseLicensesAcquired
300000 usd
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
43246230
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4489944
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2019Q4 atxi Contractual Obligation Development Expense
ContractualObligationDevelopmentExpense
81500000 usd
CY2019Q4 atxi Contractual Obligation Commercial Expense
ContractualObligationCommercialExpense
151000000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
78000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
129000 usd
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
11000 usd
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
199000 usd
CY2023Q4 atxi Accrued Contingent Fee
AccruedContingentFee
0 usd
CY2022Q4 atxi Accrued Contingent Fee
AccruedContingentFee
208000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
198000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
413000 usd
CY2016Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
55000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25597622
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4773841
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
94418
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
56.25
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
666
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
13.95
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
80615
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
40.83
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
13137
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
12.17
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
85000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.14
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
98137
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
12.17
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
906000 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
649000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1685000000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.14
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1685000000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.14
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
262500000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
1.14
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P9Y6M
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0 usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0414 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2572 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0 pure
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
997
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
9.98
CY2022 atxi Class Of Warrant Or Right Aggregate Intrinsic Value
ClassOfWarrantOrRightAggregateIntrinsicValue
11000 usd
CY2022 atxi Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
5166119
CY2022 atxi Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights
2.67
CY2022 atxi Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
1029200
CY2022 atxi Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights
0.14
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4137916
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.55
CY2023 atxi Class Of Warrant Or Right Aggregate Intrinsic Value
ClassOfWarrantOrRightAggregateIntrinsicValue
1000 usd
CY2023 atxi Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
49479398
CY2023 atxi Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights
0.26
CY2023 atxi Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
14272382
CY2023 atxi Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights
0
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
39344932
CY2023Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.49
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.11 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.10 pure
CY2023 atxi Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRatePercent
0.01 pure
CY2022 atxi Effective Income Tax Rate Reconciliation Change In Enacted State Tax Rate Percent
EffectiveIncomeTaxRateReconciliationChangeInEnactedStateTaxRatePercent
-0.01 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.22 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.03 pure
CY2023 atxi Effective Income Tax Rate Reconciliation Tax Carryforward Credit Percent
EffectiveIncomeTaxRateReconciliationTaxCarryforwardCreditPercent
0.01 pure
CY2022 atxi Effective Income Tax Rate Reconciliation Tax Carryforward Credit Percent
EffectiveIncomeTaxRateReconciliationTaxCarryforwardCreditPercent
0.04 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.01 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.11 pure
CY2023 atxi Effective Income Tax Rate Reconciliation Section162m Disallowance Limit On Compensation
EffectiveIncomeTaxRateReconciliationSection162mDisallowanceLimitOnCompensation
0 pure
CY2022 atxi Effective Income Tax Rate Reconciliation Section162m Disallowance Limit On Compensation
EffectiveIncomeTaxRateReconciliationSection162mDisallowanceLimitOnCompensation
-0.03 pure
CY2023 atxi Effective Income Tax Rate Reconciliation Change In Fair Market Value Of Warrant
EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfWarrant
0.12 pure
CY2022 atxi Effective Income Tax Rate Reconciliation Change In Fair Market Value Of Warrant
EffectiveIncomeTaxRateReconciliationChangeInFairMarketValueOfWarrant
0.48 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.45 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.49 pure
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27318000 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
25660000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
287000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
42000 usd
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2884000 usd
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1603000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
4000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
64000 usd
CY2023Q4 atxi Deferred Tax Assets Business Interest Expense Disallowance
DeferredTaxAssetsBusinessInterestExpenseDisallowance
0 usd
CY2022Q4 atxi Deferred Tax Assets Business Interest Expense Disallowance
DeferredTaxAssetsBusinessInterestExpenseDisallowance
122000 usd
CY2023Q4 atxi Deferred Tax Assets Section174 Capitalization
DeferredTaxAssetsSection174Capitalization
2253000 usd
CY2022Q4 atxi Deferred Tax Assets Section174 Capitalization
DeferredTaxAssetsSection174Capitalization
622000 usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2926000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
2859000 usd
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
35672000 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
30972000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35672000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
30972000 usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
35700000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
31000000 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000

Files In Submission

Name View Source Status
0001437749-24-008294-index-headers.html Edgar Link pending
0001437749-24-008294-index.html Edgar Link pending
0001437749-24-008294.txt Edgar Link pending
0001437749-24-008294-xbrl.zip Edgar Link pending
atxi-20231231.xsd Edgar Link pending
atxi20221231_10k.htm Edgar Link pending
ex_597578.htm Edgar Link pending
ex_597579.htm Edgar Link pending
ex_597581.htm Edgar Link pending
ex_597582.htm Edgar Link pending
ex_597583.htm Edgar Link pending
ex_597584.htm Edgar Link pending
ex_631260.htm Edgar Link pending
ex_635063.htm Edgar Link pending
ex_640800.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ksig.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
atxi-20231231_def.xml Edgar Link unprocessable
atxi-20231231_lab.xml Edgar Link unprocessable
atxi-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
atxi20221231_10k_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
atxi-20231231_cal.xml Edgar Link unprocessable